According to a recent LinkedIn post from Francis Medical, the company is highlighting what it describes as the first Vanquish procedure performed in routine commercial practice on the U.S. East Coast. The procedure was carried out by Dr. Robert Given of Urology of Virginia at Chesapeake Regional Surgery Center, and the post frames this as evidence of growing physician adoption.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post describes Vanquish as a minimally invasive system designed to ablate prostate tissue using high-energy sterile water vapor via a transurethral approach, noting that it is FDA cleared and available by prescription only. For investors, broader commercial use in new geographies may indicate early traction in the urology market and could support revenue growth potential if utilization rates and reimbursement pathways develop favorably.
The post also emphasizes clinical practice integration, suggesting that the technology is moving beyond initial trials and controlled settings into everyday care environments. If this pattern continues and more centers adopt the system, Francis Medical could strengthen its competitive position in minimally invasive prostate therapies, though the long-term financial impact will depend on procedure volumes, pricing, and competition from alternative technologies.